Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Rossi

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Cancers|July 2, 2021
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with NivolumabMatteo Bauckneht, Carlo Genova, Giovanni Rossi, et al.
Hematological Oncology|March 31, 2018
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemiaGiovanni D'Arena, Candida Vitale, Giovanni Rossi, et al.
European Journal of Clinical Investigation|August 14, 2021
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLCFederico Carbone, Stefano Ministrini, Aldo Bonaventura, et al.
Clinical & Experimental Metastasis|August 4, 2019
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancerFederico Carbone, Francesco Grossi, Aldo Bonaventura, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 2019
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot studyAldo Bonaventura, Francesco Grossi, Federico Carbone, et al.
Medical Sciences (Basel, Switzerland)|April 24, 2026
Proximal Sealing in Zone 1-2 Using the Castor Stent-Graft: Early Results from an Italian Multicenter RegistryAntonio Rizza, Simona Sica, Marco Ferraresi, et al.
Journal of Clinical Pathology|December 21, 2010
Preliminary study on the correlation between grading and histology of solitary pulmonary nodules and contrast enhancement and [18F]fluorodeoxyglucose standardised uptake value after evaluation by dynamic multiphase CT and PET/CTSalvatore Cappabianca, Annamaria Porto, Mario Petrillo, et al.
Cancer Treatment and Research Communications|September 1, 2024
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patientsFrancesca Parisi, Giuseppa De Luca, Manuela Mosconi, et al.
Cells|March 29, 2023
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint InhibitorsCarlo Genova, Roberta Tasso, Alessandra Rosa, et al.
Cancers|July 27, 2022
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer PatientsSilvia Marconi, Michela Croce, Giovanna Chiorino, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Cancers|July 2, 2021
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with NivolumabMatteo Bauckneht, Carlo Genova, Giovanni Rossi, et al.
Hematological Oncology|March 31, 2018
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemiaGiovanni D'Arena, Candida Vitale, Giovanni Rossi, et al.
European Journal of Clinical Investigation|August 14, 2021
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLCFederico Carbone, Stefano Ministrini, Aldo Bonaventura, et al.
Clinical & Experimental Metastasis|August 4, 2019
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancerFederico Carbone, Francesco Grossi, Aldo Bonaventura, et al.
Cancer Immunology, Immunotherapy : CII|July 22, 2019
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot studyAldo Bonaventura, Francesco Grossi, Federico Carbone, et al.
Medical Sciences (Basel, Switzerland)|April 24, 2026
Proximal Sealing in Zone 1-2 Using the Castor Stent-Graft: Early Results from an Italian Multicenter RegistryAntonio Rizza, Simona Sica, Marco Ferraresi, et al.
Journal of Clinical Pathology|December 21, 2010
Preliminary study on the correlation between grading and histology of solitary pulmonary nodules and contrast enhancement and [18F]fluorodeoxyglucose standardised uptake value after evaluation by dynamic multiphase CT and PET/CTSalvatore Cappabianca, Annamaria Porto, Mario Petrillo, et al.
Cancer Treatment and Research Communications|September 1, 2024
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patientsFrancesca Parisi, Giuseppa De Luca, Manuela Mosconi, et al.
Cells|March 29, 2023
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint InhibitorsCarlo Genova, Roberta Tasso, Alessandra Rosa, et al.
Cancers|July 27, 2022
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer PatientsSilvia Marconi, Michela Croce, Giovanna Chiorino, et al.
Pageof 18